PERTH, Australia – Dimerix Ltd. has begun recruiting patients for two separate phase II trials of its kidney disease candidate, DMX-200, in diabetic kidney disease and in orphan disease focal segmental glomerulosclerosis (FSGS). The Perth, Australia-based company hopes to replicate compelling data it saw in a subgroup of patients with type 2 diabetes, which could significantly open up the potential patient population for the drug.